| PHASE
I PILOT STUDY OF HER2/NEU INTRACELLULAR DOMAIN PROTEIN PULSED
AUTOLOGOUS DENDRITIC CELLS IN PATIENTS WITH HER2/NEU EXPRESSING
ADVANCED MALIGNANCIES SHOWING NO EVIDENCE OF DISEASE AFTER STANDARD
TREATMENT Protocol
PROTOCOL
IDS: DUMC-1309-00-7R1; NCI-G00-1800; DUMC-1528-99-9
STUDY
CONTACT
Michael A. Morse, Ph: 919-681-3480
Duke Comprehensive Cancer Center
Durham, North Carolina
|
PHASE
I STUDY OF 17-N-ALLYLAMINO-17-DEMETHOXY GELDANAMYCIN (17-AAG)
IN PATIENTS WITH ADVANCED SOLID TUMORS OR REFRACTORY HEMATOLOGIC
MALIGNANCIES Protocol
PROTOCOL
IDS: MSKCC-99037, NCI-T99-0035
STUDY
CONTACT
Howard I. Scher, Chair Ph: 212-639-7585
Memorial Sloan-Kettering Cancer Center
New York, New York
|
| PHASE
I PILOT STUDY OF P53 (264-272) PEPTIDE VACCINE AND TUMOR SPECIFIC
MUTANT P53 PEPTIDE VACCINE IN HLA-A2.1 PATIENTS WITH STAGE IV,
RECURRENT, OR PROGRESSIVE ADENOCARCINOMA OF THE BREAST Protocol
PROTOCOL
IDS: NCI-99-C-0138; NCI-T99-0075; NCI-NMOB-9902
STUDY
CONTACT
Samir N. Khleif, Ph: 301-496-0901
Medicine Branch
Bethesda, Maryland
|
PHASE
I STUDY OF ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
IN PATIENTS WITH METASTATIC OR UNRESECTABLE SMALL CELL LUNG
CANCER, BREAST CANCER, TESTICULAR GERM CELL CANCER, MELANOMA,
OR RENAL CELL CANCER Protocol
PROTOCOL
IDS: NU-99H2; NCI-G00-1838
STUDY
CONTACT
Steven T. Rosen, Ph: 312-908-5250
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinoi
|
| PHASE
I PILOT STUDY OF SEQUENTIAL HIGH DOSE CISPLATIN/ CYCLOPHOSPHAMIDE/ETOPOSIDE
AND IFOSFAMIDE/CARBOPLATIN/PACLITAXEL WITH AUTOLOGOUS STEM CELL
SUPPORT FOR ADVANCED CARCINOMAS Protocol
PROTOCOL
IDS: CHNMC-IRB-94098; NCI-V96-1042
STUDY
CONTACT
George Somlo, Ph: 626-359-8111
Beckman Research Institute, City of Hope
Los Angeles, California
|
PHASE
I STUDY OF CARBOXYAMIDOTRIAZOLE PLUS PACLITAXEL IN PATIENTS
WITH ADVANCED SOLID TUMORS OR REFRACTORY LYMPHOMAS Protocol
PROTOCOL
IDS: NCI-95-C-0015F; NCI-T94-0006N; NCI-CPB-334
STUDY
CONTACT
Elise C. Kohn, Chair, Ph: 301-402-2726
Center for Cancer Research
Washington, DC
|
| PHASE
I RANDOMIZED STUDY OF MAGE-12 PEPTIDE VACCINE IN PATIENTS WITH
REFRACTORY METASTATIC CANCER EXPRESSING MAGE-12 ANTIGEN Protocol
PROTOCOL
IDS: NCI-00-C-0182; NCI-1034
STUDY
CONTACT
Francesco M. Marincola, Ph: 301-496-3098
Surgery Branch
Bethesda, Maryland
|
PHASE
I STUDY OF CD80-MODIFIED ALLOGENEIC BREAST CANCER CELL LINE
TO VACCINATE HLA-A2 POSITIVE WOMEN WITH BREAST CANCER Protocol
PROTOCOL
IDS: PPMC-IRB-94-78; NCI-V98-1379; OCC-ONC-9408-L
STUDY
CONTACT
John W. Smith, II, Ph: 503-232-7000
Earle A. Chiles Research Institute at Providence
Portland, Oregon
|
| PHASE
I STUDY OF CRYOSURGERY IN WOMEN WITH HIGHLY SUSPICIOUS BREAST
LESIONS
Protocol
PROTOCOL
IDS: UCLA-9908076; NCI-G01-1964
STUDY
CONTACT
Helena R. Chang, Chair, Ph: 310-794-5624
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
|
PHASE
I STUDY OF INTRAPERITONEAL AMINOCAMPTOTHECIN COLLOIDAL DISPERSION
IN PATIENTS WITH CANCER PREDOMINANTLY CONFINED TO THE PERITONEAL
CAVITY Protocol
PROTOCOL
IDS: NYU-9753; NCI-T97-0123
STUDY
CONTACT
Franco M. Muggia, Ph: 212-263-6485
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York, New York
|
| PHASE
I STUDY OF DOCETAXEL, GEMCITABINE, AND FILGRASTIM (G-CSF) IN
PATIENTS WITH ADVANCED SOLID TUMORS Protocol
PROTOCOL
IDS: DMS-9933; NCI-G01-1933
STUDY
CONTACT
Konstantin H. Dragnev, Chai, Ph: 603-650-6345
Norris Cotton Cancer Center
Lebanon, New Hampshire
|
PHASE
I STUDY OF INTRATHECAL MAFOSFAMIDE IN PATIENTS WITH REFRACTORY
MENINGEAL MALIGNANCIES Protocol
PROTOCOL
IDS: NCI-90-C-95H, NCI-T89-0174N
STUDY
CONTACT
Frank Milton Balis, Chair Ph: 301-496-0085
Center for Cancer Research
Bethesda, Maryland
|
| PHASE
I STUDY OF INTERLEUKIN-12 AND INTERLEUKIN-2 IN PATIENTS WITH
REFRACTORY OR ADVANCED SOLID TUMORS Protocol
PROTOCOL
IDS: NCI-00-C-0121; NCI-41
STUDY
CONTACT
Jon M. Wigginton, Chair, Ph: 301-846-5468
Center for Cancer Research
Bethesda, Maryland
|
PHASE
I STUDY OF IRINOTECAN AND GEMCITABINE IN PATIENTS WITH UNRESECTABLE
OR METASTATIC SOLID TUMORS Protocol
PROTOCOL
IDS: NU-98X3; NCI-G99-1588; P-UPJOHN-976475157
STUDY
CONTACT
Al Bowen Benson, III, Ph: 312-695-6180
Robert H. Lurie Comprehensive Cancer Center,
Northwestern University
Chicago, Illinois
|
| PHASE
I STUDY OF INTERLEUKIN-12 AND TRASTUZUMAB (HERCEPTIN) IN PATIENTS
WITH HER2-NEU OVEREXPRESSING MALIGNANCIES Protocol
PROTOCOL
IDS: OSU-99H0185; NCI-T99-0032
STUDY
CONTACT
Charles L. Shapiro, Ph: 614-293-7530
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio
|
PHASE
I STUDY OF IRINOTECAN AND ORAL CAPECITABINE IN PATIENTS WITH
GASTROINTESTINAL OR OTHER SOLID TUMORS Protocol
PROTOCOL
IDS: AECM-1199903068, NCI-V99-1541
STUDY
CONTACT
Sridhar Mani, Chair Ph: 718-904-2488
Albert Einstein Comprehensive Cancer Center
New York, New York
|
| PHASE
I STUDY OF LMB-9 IMMUNOTOXIN IN PATIENTS WITH ADVANCED COLON,
BREAST, NON-SMALL CELL LUNG, BLADDER, PANCREAS, OR OVARIAN CANCER
Protocol
PROTOCOL
IDS: MSGCC-9981; NCI-511; MSGCC-IRB-0200123
STUDY
CONTACT
Petr F. Hausner, Ph: 410-328-2565
Marlene & Stewart Greenebaum Cancer Center,
University of Maryland
Baltimore, Maryland
|
PHASE
I STUDY OF NEOADJUVANT CAPECITABINE, CYCLOPHOSPHAMIDE, AND EPIRUBICIN
IN WOMEN WITH LOCALLY ADVANCED OR INFLAMMATORY OR LARGE OPERABLE
BREAST CANCER Protocol
PROTOCOL
IDS: IDBBC-10991-CEX
STUDY
CONTACT
Herve Bonnefoi, Ph: 011-44-22-382-33-11
Hopital Cantonal Universitaire de Geneva
Geneva, Switzerland
|
| PHASE
I STUDY OF LMB-9 IMMUNOTOXIN IN PATIENTS WITH ADVANCED SOLID
TUMORS THAT EXPRESS LEWIS Y ANTIGEN Protocol
PROTOCOL
IDS: NCI-98-C-0078A; NCI-T98-0005; NCI-MB-400
STUDY
CONTACT
Robert Kreitman, Ph: 301-496-6947
Medicine Branch
Bethesda, Maryland
|
PHASE
I STUDY OF PERIFOSINE IN PATIENTS WITH REFRACTORY SOLID TUMORS
Protocol
PROTOCOL
IDS: NCI-99-C-0043, NCI-T98-0065
STUDY
CONTACT
Manish Monga, Chair Ph: 301-435-0536
Center for Cancer Research
Bethesda, Maryland
|
| PHASE
I STUDY OF MUTANT MGMT GENE TRANSFER INTO HUMAN HEMATOPOIETIC
PROGENITORS TO PROTECT HEMATOPOIESIS DURING O6-BENZYGUANINE
AND CARMUSTINE THERAPY OF ADVANCED SOLID TUMORS AND NON-HODGKIN'S
LYMPHOMA Protocol
PROTOCL
IDS: CWRU-2Y97; NCI-T97-0060
STUDY
CONTACT
Stanton L. Gerson, Chair, Ph: 216-368-1176
Ireland Cancer Center
Cleveland, Ohio
|
PHASE
I STUDY OF PERILLYL ALCOHOL IN WOMEN AT RISK FOR RECURRENT BREAST
CANCER Protocol
PROTOCOL
IDS: CCF-IRB-3574, NCI-P01-0189,CCF-N01-CN-55131
STUDY
CONTACT
G. Thomas Budd, Chair Ph: 216-444-6480
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
|
| PHASE
I STUDY OF MVF-HER-2(628-647)-CRL 1005 VACCINE IN PATIENTS WITH
METASTATIC OR RECURRENT CANCER Protocol
PROTOCOL
IDS: UAB-0020, NCI-G01-1955
STUDY
CONTACT
Pierre Lorenzo Triozzi, Chair Ph: 205-975-2833
University of Alabama Comprehensive Cancer Center
|
PHASE
I STUDY OF POST TRANSPLANT INTERLEUKIN-12 FOLLOWING HIGH DOSE
CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN IN WOMEN WITH METASTATIC
BREAST CARCINOMA Protocol
PROTOCOL
IDS: BIH-L97-0252; NCI-T98-0002
STUDY
CONTACT
David Avigan, Ph: 617-667-9920
Beth Israel Deaconess Medical Center
Boston, Massachusetts
|
| PHASE
I STUDY OF RECOMBINANT HUMAN INTERLEUKIN-12 AFTER HIGH-DOSE
CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC STEM CELL SUPPORT
IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS Protocol
PROTOCOL
IDS: IUMC-9708-05, NCI-T97-0027
STUDY
CONTACT
Michael J. Robertson, Chair Ph: 317-274-0843
Indiana University Cancer Center
Indianapolis, Indiana
|
PHASE
I STUDY OF YTTRIUM Y 90 LABELED, HUMANIZED MONOCLONAL ANTIBODY
BRE-3 AND INDIUM IN 111 LABELED, HUMANIZED MONOCLONAL ANTIBODY
BRE-3 FOLLOWED BY AUTOLOGOUS BONE MARROW OR PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION IN PATIENTS WITH METASTATIC BREAST
CANCER Protocol
PROTOCOL
IDS: CRICC-BB-IND-7186; NCI-V00-1637; UCHSC-97467
STUDY
CONTACT
Jerry A. Peterson, Ph: 415-431-3330
Cancer Research Institute of Contra Costa
San Francisco, California
|
| PHASE
I STUDY OF RECOMBINANT VACCINIA DF3/MUC1 VACCINE IN PATIENTS
WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: DFCI-97050; NCI-T98-0057
STUDY
CONTACT
Donald W. Kufe, Ph: 617-632-3141
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Boston, Massachusetts
|
PHASE
I STUDY OF YTTRIUM Y 90 MONOCLONAL ANTIBODY B3 FOLLOWED BY AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH
RELAPSED OR METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: NCI-00-C-0206; NCI-213
STUDY
CONTACT
Michael Bishop, Chair, Ph: 301-435-2764
Division of Clinical Sciences
Bethesda, Maryland
|
| PHASE
I STUDY OF SU5416 AND DOXORUBICIN IN PATIENTS WITH STAGE IIIB
OR IV INFLAMMATORY BREAST CANCER Protocol
PROTOCOL
IDS: CWRU-5199; NCI-T99-0099
STUDY
CONTACT
Beth A. Overmoyer, Ph: 216-844-5176
Ireland Cancer Center
Cleveland, Ohio
|
PHASE
I STUDY OF YTTRIUM Y 90 MONOCLONAL ANTIBODY M170, CYCLOSPORINE
AND PACLITAXEL IN PATIENTS WITH RECURRENT OR REFRACTORY METASTATIC
BREAST CANCER Protocol
PROTOCOL
IDS: UCD-992080, NCI-V00-1640
STUDY
CONTACT
Carol M. Richman, Chair Ph: 916-734-3771
University of California Davis Cancer Center
Sacramento, California
|
| PHASE
I STUDY OF THE ETANIDAZOLE DERIVATIVE EF5 FOR THE DETECTION
OF HYPOXIA IN PATIENTS WITH BREAST, HEAD AND NECK, PROSTATE,
OR CERVICAL CARCINOMA OR HIGH GRADE SOFT TISSUE SARCOMAS Protocol
PROTOCOL
IDS: CAN-OCI-T98-0048; NCI-T98-0048
STUDY
CONTACT
Anthony Fyles, Ph: 416-946-2123
Princess Margaret Hospital
Toronto, Ontario, Canada
|
PHASE
I STUDY OF YTTRIUM Y 90-SMT 487 IN PATIENTS WITH REFRACTORY
OR RECURRENT SOMATOSTATIN RECEPTOR POSITIVE MALIGNANT NEOPLASMS
Protocol
PROTOCOL
IDS: MCC-12275; NCI-G00-1857; MCC-IRB-5473; NOVARTIS-SMT-B151
STUDY
CONTACT
Larry K. Kvols, Ph: 813-972-8400, ext. 8286
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
|
| PHASE
I/II PILOT STUDY OF STEM CELL MOBILIZATION WITH PACLITAXEL AND
CYCLOPHOSPHAMIDE FOLLOWED BY HIGH DOSE MELPHALAN AND ETOPOSIDE
WITH AUTOLOGOUS PERIPHERAL BLOOD STEM CELL RESCUE IN PATIENTS
WITH METASTATIC OR HIGH RISK BREAST CANCER Protocol
PROTOCOL
IDS: NCI-96-C-0104G; NCI-T95-0078N
STUDY
CONTACT
Ronald E. Gress, Ph: 301-435-4654
Medicine Branch
Bethesda, Maryland
|
PHASE
I/II STUDY OF BECLOMETHASONE IN PATIENTS WITH INTESTINAL GRAFT-VERSUS-HOST
DISEASE WITH CONTRAINDICATION TO HIGH-DOSE IMMUNOSUPPRESSIVE
THERAPY Protocol
PROTOCOL
IDS: FHCRC-1500.00, NCI-H01-0067
STUDY
CONTACT
David Hockenbery, Chair Ph: 206-667-4611
Fred Hutchinson Cancer Research Center
Seattle, Washington
|
| PHASE
I/II RANDOMIZED STUDY OF EX VIVO EXPANDED MEGAKARYOCYTES IN
PATIENTS WITH BREAST CANCER OR HEMATOLOGIC MALIGNANCIES Protocol
PROTOCOL
IDS: NU-97B2; NCI-V00-1611
STUDY
CONTACT
Jane N. Winter, Ph: 312-695-6180
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois
|
PHASE
I/II STUDY OF CAPECITABINE AND VINORELBINE IN ELDERLY WOMEN
WITH METASTATIC BREAST CANCER WITH OR WITHOUT BONE INVOLVEMENT
Protocol
PROTOCOL
IDS: SWS-SAKK-25/99; EU-99007
STUDY
CONTACT
D. Hess, Ph: 071-494-11-11
Kantonsspital - Saint Gallen
Saint Gallen, Switzerland
|
| PHASE
I/II STUDY OF ACTIVE IMMUNOTHERAPY WITH CARCINOEMBRYONIC ANTIGEN
(CEA) RNA PULSED AUTOLOGOUS DENDRITIC CELLS IN PATIENTS WITH
METASTATIC BREAST CANCER WHO ACHIEVE A COMPLETE RESPONSE AFTER
HIGH DOSE CHEMOTHERAPY AND STEM CELL SUPPORT Protocol
PROTOCOL
IDS: DUMC-97148; NCI-G98-1455
STUDY
CONTACT
Herbert Kim Lyerly, Ph: 919-681-8350
Duke Comprehensive Cancer Center
Durham, North Carolina
|
PHASE
I/II STUDY OF CAPECITABINE, PACLITAXEL, AND TRASTUZUMAB (HERCEPTIN)
IN PATIENTS WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: UNC-9904; NCI-G00-1834
STUDY
CONTACT
Frances A. Collichio, Ph: 919-966-4431
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
|
| PHASE
I/II STUDY OF AUGMEROSEN WITH DOCETAXEL IN PATIENTS WITH ANDROGEN
INDEPENDENT PROSTATE CANCER OR OTHER ADVANCED SOLID TUMORS Protocol
PROTOCOL
IDS: MSKCC-97096, NCI-G97-1337, GENTA-G3139-97/01
STUDY
CONTACT
Michael Morris, Chair Ph: 212-639-5132
Memorial Sloan-Kettering Cancer Center
New York, New York
|
PHASE
I/II STUDY OF DOCETAXEL AND FLAVOPIRIDOL IN PATIENTS WITH PREVIOUSLY
TREATED LOCALLY ADVANCED OR METASTATIC ADENOCARCINOMA OF THE
BREAST Protocol
PROTOCOL
IDS: NCI-00-C-0212; NCI-952
STUDY
CONTACT
Sandra M. Swain, Ph: 301-496-4916
Medicine Branch
Bethesda, Maryland
|
| PHASE
I/II STUDY OF DOXORUBICIN HCL LIPOSOME AND TRASTUZUMAB (HERCEPTIN)
IN WOMEN WITH LOCALLY ADVANCED, INFLAMMATORY, OR METASTATIC
BREAST CANCER Protocol
PROTOCOL
IDS: MSKCC-99054; NCI-G00-1684; LIPO-D9905
STUDY
CONTACT
Clifford Hudis, Ph: 212-639-6483
Memorial Sloan-Kettering Cancer Center
New York, New York
|
PHASE
I/II STUDY OF SAMARIUM 153 AND AUTOLOGOUS BONE MARROW TRANSPLANTATION
FOR STAGE IV BREAST CANCER Protocol
PROTOCOL
IDS: LSU-97447; NCI-V97-1341
STUDY
CONTACT
Benjamin Barry Weinberger, Ph: 318-675-5972
Louisiana State University School of Medicine
Shreveport, Louisiana
|
| PHASE
I/II STUDY OF DOXORUBICIN HCL LIPOSOME AND TRASTUZUMAB (HERCEPTIN)
IN WOMEN WITH ADVANCED HER-2/NEU-OVEREXPRESSING BREAST CANCER
Protocol
PROTOCOL
IDS: NYU-0012; NCI-G00-1878; ALZA-00-001-ii
STUDY
CONTACT
Franco M. Muggia, Ph: 212-263-6485
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York, New York
|
PHASE
I/II STUDY OF SEQUENTIAL PACLITAXEL, DOXORUBICIN, AND CYCLOPHOSPHAMIDE
FOLLOWED BY IMMUNOTHERAPY WITH ACTIVATED T CELLS, INTERLEUKIN-2,
AND SARGRAMOSTIM (GM-CSF) IN WOMEN WITH HIGH-RISK STAGE II OR
III BREAST CANCER Protocol
PROTOCOL
IDS: RWMC-0033846
STUDY
CONTACT
Lawrence G. Lum, Chair Ph: 401-456-2672
Roger Williams Medical Center/BUSM
Providence, Rhode Island
|
| PHASE
I/II STUDY OF HIGH DOSE MELPHALAN WITH AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL SUPPORT AND AMIFOSTINE CYTOPROTECTION IN CANCER
PATIENTS Protocol
PROTOCOL
IDS: UKMC-97BMT72, NCI-V98-1455, ALZA-UKMC-97BMT72
STUDY
CONTACT
Donna E. Reece, Chair Ph: 416-946-2253
University of Toronto, Princess Margaret Hospital
Toronto, Canada
|
PHASE
I/II STUDY OF TRASTUZUMAB (HERCEPTIN) FOLLOWING HIGH DOSE CHEMOTHERAPY
AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
PATIENTS WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: BIH-99-12; NCI-V00-1610;BIH-W-99-0053-FB
STUDY
CONTACT
David Avigan, Ph: 617-667-9920
Beth Israel Deaconess Medical Center
Boston, Massachusetts
|
| PHASE
I/II STUDY OF HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AND IMMUNOTHERAPY
WITH ACTIVATED T CELLS, INTERLEUKIN-2, AND SARGRAMOSTIM (GM-CSF)
IN PATIENTS WITH STAGE IIIB OR IV BREAST CANCER OR OTHER SOLID
TUMORS Protocol
PROTOCOL
IDS: RWMC-0034246
STUDY
CONTACT
Lawrence G. Lum, Chair Ph: 401-456-2672
Roger Williams Medical Center/BUSM
Providence, Rhode Island
|
PHASE
II PILOT STUDY COMPARING DOXORUBICIN (ADRIAMYCIN) AND PACLITAXEL
(TAXOL) INDUCED LOCALLY ADVANCED BREAST CANCER Protocol
PROTOCOL
IDS: GUMC-97018; NCI-V97-1276
STUDY
CONTACT
Daniel F. Hayes, Ph: 202-687-3013
Vincent T. Lombardi Cancer Research Center
Georgetown University
Washington, District of Columbia
|
| PHASE
II PILOT STUDY OF ADJUVANT PACLITAXEL, CYCLOPHOSPHAMIDE, FILGRASTIM
(G-CSF), AND DOXORUBICIN FOLLOWED BY RADIOTHERAPY IN PATIENTS
WITH STAGE II OR IIIA BREAST CANCER Protocol
PROTOCOL
IDS: CWRU-1100; NCI-G00-1877; CWRU-050023
STUDY
CONTACT
Brenda W. Cooper, Ph: 216-844-3213
Ireland Cancer Center
Cleveland, Ohio
|
PHASE
II PILOT STUDY OF TRASTUZUMAB (HERCEPTIN) PLUS DOCETAXEL IN
WOMEN WITH HER2-NEU OVEREXPRESSING RECURRENT OR METASTATIC BREAST
CANCER Protocol
PROTOCOL
IDS: VU-VCC-BRE-9823; NCI-G00-1830
STUDY
CONTACT
Brenda P. Nicholson, Ph: 615-322-4967
Vanderbilt Cancer Center
Nashville, Tennessee
|
| PHASE
II PILOT STUDY OF BEVACIZUMAB, DOCETAXEL, DOXORUBICIN, AND FILGRASTIM
(G-CSF) IN PATIENTS WITH PREVIOUSLY UNTREATED STAGE IIIB OR
IV INFLAMMATORY BREAST CANCER Protocol
PROTOCOL
IDS: NCI-01-C-0173, NCI-2772
STUDY
CONTACT
Nicole McCarthy, Chair Ph: 301-496-4916
Center for Cancer Research
Bethesda, Maryland
|
PHASE
II PILOT STUDY OF TUMOR-SPECIFIC P53 OR RAS VACCINES WITH OR
WITHOUT CELLULAR IMMUNOTHERAPY WITH PEPTIDE-ACTIVATED LYMPHOCYTES
PLUS INTERLEUKIN-2 IN PATIENTS WITH TUMORS EXPRESSING MUTANT
P53 OR RAS Protocol
PROTOCOL
IDS: NCI-95-C-0105A; NCI-T94-0096N
STUDY
CONTACT
Samir N. Khleif, Ph: 301-496-0901
Medicine Branch
Bethesda, Maryland
|
| PHASE
II PILOT STUDY OF CYCLOPHOSPHAMIDE AND ACTIVE INTRALYMPHATIC
IMMUNOTHERAPY WITH A VACCINE CONTAINING INTERFERON ALFA OR INTERFERON
GAMMA TREATED TUMOR CELLS FOLLOWED BY SARGRAMOSTIM (GM-CSF)
IN PATIENTS WITH ADVANCED CANCERS Protocol
PROTOCOL
IDS: SVMC-ONC-222, NCI-V91-0075
STUDY
CONTACT
Charles L. Wiseman, Chair Ph: 213-484-7575
St. Vincent Medical Center - Los Angeles
Los Angeles, California
|
PHASE
II RANDOMIZED STUDY OF DOXORUBICIN, CYCLOPHOSPHAMIDE, AND PACLITAXEL
(ACT) VS CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN (STAMP
V) IN PATIENTS WITH HIGH-RISK PRIMARY BREAST CANCER Protocol
PROTOCOL
IDS: CHNMC-IRB-98096; NCI-H99-0038;CHNMC-PHII-18
STUDY
CONTACT
George Somlo, Ph: 626-359-8111
Beckman Research Institute, City of Hope
Los Angeles, California
|
| PHASE
II PILOT STUDY OF HIGH DOSE DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL,
AND AMIFOSTINE FOLLOWED BY PERIPHERAL STEM CELL RESCUE IN PATIENTS
WITH HIGH RISK STAGE II/III AND RESPONSIVE STAGE IV ADVANCED
BREAST CANCER Protocol
PROTOCOL
IDS: CHNMC-IRB-99002; NCI-G99-1527; ALZA-CHNMC-IRB-99002
STUDY
CONTACT
George Somlo, Ph: 626-359-8111
Beckman Research Institute, City of Hope
Los Angeles, California
|
PHASE
II RANDOMIZED STUDY OF ERA-923 IN POST MENOPAUSAL WOMEN WITH
METASTATIC BREAST CANCER REFRACTORY TO TAMOXIFEN Protocol
PROTOCOL
IDS: MCC-12235; NCI-G00-187; GENE-C9944- 33; MCC-IRB-5757;
W-AR-3077A1-200-US
STUDY
CONTACT
Susan Minton, Ph: 813-972-4673
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
|
| PHASE
II RANDOMIZED STUDY OF EXEMESTANE AND RALOXIFENE IN POSTMENOPAUSAL
WOMEN WITH A HISTORY OF STAGE 0 (DUCTAL CARCINOMA IN SITU),
I, II, OR III BREAST CANCER WHO HAVE NO CLINICAL EVIDENCE OF
DISEASE Protocol
PROTOCOL
IDS: MSKCC-99017; NCI-G99-1662
STUDY
CONTACT
Clifford Hudis, Ph: 212-639-6483
Memorial Sloan-Kettering Cancer Center
New York, New York
|
PHASE
II RANDOMIZED STUDY OF PACLITAXEL, CARBOPLATIN, AND TRASTUZUMAB
(HERCEPTIN) AS FIRST-LINE CHEMOTHERAPY IN WOMEN WITH OVEREXPRESSED
HER-2, METASTATIC BREAST CANCER Protocol
PROTOCOL
ID: NCCTG-983252
STUDY
CONTACT
Edith A. Perez, Ph: 904-953-7283
Mayo Clinic Cancer Center
Rochester, Minnesota
|
| PHASE
II RANDOMIZED STUDY OF IRINOTECAN FOR REFRACTORY METASTATIC
BREAST CANCER Protocol
PROTOCOL
IDS: NCCTG-963255
STUDY
CONTACT
Edith A. Perez, Ph: 904-953-7283
Mayo Clinic Cancer Center
Rochester, Minnesota
|
PHASE
II RANDOMIZED STUDY OF SOY ISOFLAVONE IN PATIENTS WITH BREAST
CANCER Protocol
PROTOCOL
IDS: UCLA-000509301, NCI-G01-1994
STUDY
CONTACT
Mai Nguyen, Chair Ph: 310-206-2215
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
|
| PHASE
II RANDOMIZED STUDY OF METHOTREXATE WITH OR WITHOUT ANTINEOPLASTON
A10 CAPSULES IN WOMEN WITH ADVANCED BREAST CANCER Protocol
PROTOCOL
IDS: BRI-BR-10; B-New-65
STUDY
CONTACT
Stanislaw R. Burzynski, Ph: 713-335-5697
Burzynski Research Institute
Houston, Texas
|
PHASE
II RANDOMIZED STUDY OF SUBCUTANEOUS TRASTUZUMAB (HERCEPTIN)
PLUS PACLITAXEL IN WOMEN WITH HER2 OVEREXPRESSING METASTATIC
BREAST CANCER Protocol
PROTOCOL
IDS: MSKCC-99118; NCI-G00-1769;GENENTECH-H1994g
STUDY
CONTACT
Andrew D. Seidman, Ph: 212-636-5875
Memorial Sloan-Kettering Cancer Center
New York, New York
|
| PHASE
II RANDOMIZED STUDY OF MULTI-COURSE HIGH-DOSE CHEMOTHERAPY WITH
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION VERSUS
STANDARD-DOSE CHEMOTHERAPY IN WOMEN WITH METASTATIC BREAST CANCER
Protocol
PROTOCOL
IDS: CPMC-IRB-9244, NCI-G01-1922
STUDY
CONTACT
Linda T. Vahdat, Chair Ph: 212-305-2486
Herbert Irving Comprehensive Cancer Center
New York, New York
|
PHASE
II RANDOMIZED STUDY OF TWO DIFFERENT DOSE SCHEDULES OF DOXORUBICIN
HCL LIPOSOME IN WOMEN WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: IDBBC-10993
STUDY
CONTACT
Robert E. Coleman, Ph: 114-226-5213
Weston Park Hospital
Sheffield, England, United Kingdom
|
| PHASE
II RANDOMIZED STUDY OF TWO DIFFERENT SCHEDULES OF DOCETAXEL
OR PACLITAXEL IN WOMEN WITH UNRESECTABLE LOCALLY ADVANCED OR
METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: FRE-GERCOR-TAXMAX-SOO-; EU-20029; GERCOR
STUDY
CONTACT
Joseph Gligorov, Chair, Ph: 1-40-30-6024
|
PHASE
II STUDY OF ALLOGENEIC MIXED CHIMERISM PERIPHERAL BLOOD STEM
CELL RANSPLANTATION UTILIZING IN VIVO AND IN VITRO MONOCLONAL
ANTIBODY CD52 (CAMPATH-1H) IN PATIENTS WITH HIGH RISK HEMATOLOGIC
MALIGNANCIES OR DISEASES Protocol
PROTOCOL
IDS: DUMC-1340-99-7; NCI-G99-1617
STUDY
CONTACT
David A. Rizzieri, Ph: 919-668-1040
Duke Comprehensive Cancer Center
Durham, North Carolina
|
| PHASE
II RANDOMIZED STUDY OF VINORELBINE/EPIRUBICIN VERSUS VINORELBINE/MITOXANTRONE
VERSUS CYCLOPHOSPHAMIDE/DOXORUBICIN AS PREOPERATIVE CHEMOTHERAPY
IN WOMEN WITH EARLY STAGE BREAST CANCER Protocol
PROTOCOL
IDS: RMNHS-TOPIC2; EU-99037
STUDY
CONTACT
Ian Edward Smith, Ph: 0181-661-3280
Royal Marsden Hospital
Sutton, England, United Kingdom
|
PHASE
II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH STAGE
IV BREAST CARCINOMA Protocol
PROTOCOL
IDS: BRI-BR-12
STUDY
CONTACT
Stanislaw R. Burzynski, Ph: 713-335-5697
Burzynski Research Institute
Houston, Texas
|
| PHASE
II STUDY OF 6-HYDROXYMETHYLACYLFULVENE (MGI-114) IN PATIENTS
WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: UTHSC-IDD-98-23; NCI-T98-0060; SACI-IDD-98-23
STUDY
CONTACT
Lisa Hammond, Chair Ph: 210-616-5970
University of Texas Health Science Center at San Antonio
San Antonio, Texas
|
PHASE
II STUDY OF BMS-247550 IN WOMEN WITH TAXANE-RESISTANT METASTATIC
BREAST CANCER Protocol
PROTOCOL
IDS: MSKCC-01031, NCI-G01-1967, BMS-CA163-009
STUDY
CONTACT
Clifford A. Hudis, Chair Ph: 212-639-6483
Memorial Sloan-Kettering Cancer Center
New York, New York
|
| PHASE
II STUDY OF ADJUVANT DOSE INTENSIVE, SEQUENTIAL CHEMOTHERAPY
WITH DOXORUBICIN, PACLITAXEL, AND CYCLOPHOSPHAMIDE FOR RESECTED
STAGE II/III BREAST CANCER Protocol
PROTOCOL
IDS: YALE-HIC-7374; NCI-V95-0720
STUDY
CONTACT
Barbara A. Burtness, Ph: 203-785-6007
Yale Comprehensive Cancer Center
New Haven, Connecticut
|
PHASE
II STUDY OF BRYOSTATIN 1 FOR THE TREATMENT OF STAGE IV BREAST
CANCER Protocol
PROTOCOL
IDS: UCHSC-97751; NCI-T97-0063
STUDY
CONTACT
Andrew S. Kraft, Ph: 303-315-8802
University of Colorado Cancer Center
Denver, Colorado
|
| PHASE
II STUDY OF CELECOXIB AND TRASTUZUMAB (HERCEPTIN) IN WOMEN WITH
HER2/NEU OVEREXPRESSING METASTATIC BREAST CANCER THAT IS REFRACTORY
TO PRIOR TRASTUZUMAB Protocol
PROTOCOL
IDS: MSKCC-00078; NCI-G00-1869
STUDY
CONTACT
Clifford A. Huddis, Ph: 212-639-6483
Memorial Sloan-Kettering Cancer Center
New York, New York
|
PHASE
II STUDY OF DOCETAXEL AND CARBOPLATIN AS FIRST LINE THERAPY
IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE BREAST Protocol
PROTOCOL
IDS: NCCTG-N9932
STUDY
CONTACT
Michael J. O'Connell, Chair, Ph: 507-284-2511
North Central Cancer Treatment Group
Rochester, Minnesota
|
| PHASE
II STUDY OF CONCURRENT BEVACIZUMAB AND VINORELBINE IN PATIENTS
WITH STAGE IV BREAST CANCER Protocol
PROTOCOL
IDS: DFCI-01013, NCI-2716
STUDY
CONTACT
Harold J. Burstein, Chair Ph: 617-632-3800
Dana-Farber Cancer Institute
Boston, Massachusetts
|
ESTRAMUSTINE
IN PATIENTS WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: CPMC-IRB-7929; NCI-V97-1325
STUDY
CONTACT
Amy D. Tliersten, Ph: 212-305-0170
Herbert Irving Comprehensive Cancer Center
New York, New York
|
| PHASE
II STUDY OF CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN FOLLOWED
BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN WOMEN
WITH BREAST CANCER Protocol
PROTOCOL
IDS: MCC-11072; NCI-G00-1760; MCC-IRB-3898
STUDY
CONTACT
Karen K. Fields, Ph: 813-979-7202
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
|
PHASE
II STUDY OF DOCETAXEL IN CAUCASIAN AND AFRICAN AMERICAN PATIENTS
WITH SOLID TUMORS Protocol
PROTOCOL
IDS: CLB-9871
STUDY
CONTACT
Lionel D. Lewis, Chair Ph: 603-650-8685
Cancer and Leukemia Group B
|
| PHASE
II STUDY OF CYTOKINE-BASED IMMUNOTHERAPY FOLLOWING HIGH DOSE
CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS
WITH HIGH RISK CANCER Protocol
PROTOCOL
IDS: MRMC-CTCA-9801, NCI-V98-1449
STUDY
CONTACT
Oscar Francisco Ballester, Chair, Ph: 847-872-4561
Midwestern Regional Medical Center
Zion, Illinois
|
PHASE
II STUDY OF DOCETAXEL, DOXORUBICIN, AND CYCLOPHOSPHAMIDE AS
PRIMARY THERAPY IN WOMEN WITH STAGE III BREAST CANCER Protocol
PROTOCOL
IDS: NU-98B1; NCI-G99-1643
STUDY
CONTACT
William John Gradishar, Chair Ph: 312-695-4541
Robert H. Lurie Comprehensive Cancer Center,
Northwestern University
Chicago, Illinois
|
| PHASE
II STUDY OF DOCETAXEL, LEUCOVORIN CALCIUM, AND FLUOROURACIL
AS SECOND OR THIRD-LINE CHEMOTHERAPY IN WOMEN WITH LOCALLY UNRESECTABLE
OR METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: CCCWFU-74896; NCI-3137
STUDY
CONTACT
Gretchen Kimmick, Chair Ph: 336-716-0327
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina
|
PHASE
II STUDY OF ETOPOSIDE, IFOSFAMIDE, MESNA, AND CISPLATIN IN PATIENTS
WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: CWRU-4196; NCI-G00-1854;BMS-CRWU-4196
STUDY
CONTACT
Paula Silverman, Ph: 216-844-8510
Ireland Cancer Center
Cleveland, Ohio
|
| PHASE
II STUDY OF DOCETAXEL, VINORELBINE, AND FILGRASTIM (G-CSF) IN
WOMEN WITH HER-2 NEGATIVE STAGE IV BREAST CANCER Protocol
PROTOCOL
ID: SWOG-S0102
STUDY
CONTACT
Julie R. Gralow, Chair Ph: 206-288-7722
Southwest Oncology Group
|
PHASE
II STUDY OF GEMCITABINE AND DOXORUBICIN HCL LIPOSOME IN WOMEN
WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: MDA-DM-97127; NCI-1650
STUDY
CONTACT
Edgardo Rivera, Ph: 713-792-2817
University of Texas - MD Anderson Cancer Center
Houston, Texas
|
| PHASE
II STUDY OF DOSE INTENSIVE CHEMOTHERAPY AND STEM CELL RESCUE
IN PATIENTS WITH INFLAMMATORY STAGE IIIB BREAST CANCER Protocol
PROTOCOL
IDS: CHNMC-96139; NCI-G97-1288
STUDY
CONTACT
George Somlo, Ph: 626-359-8111
Beckman Research Institute, City of Hope
Los Angeles, California
|
PHASE
II STUDY OF GEMCITABINE IN WOMEN WITH METASTATIC BREAST CANCER
PREVIOUSLY TREATED WITH DOXORUBICIN AND PACLITAXEL Protocol
PROTOCOL
IDS: MSKCC-98030; NCI-G98-1474
STUDY
CONTACT
Violante E. Currie, Chair Ph: 212-639-6991
Memorial Sloan-Kettering Cancer Center
New York, New York
|
| PHASE
II STUDY OF DOXORUBICIN HCL LIPOSOME AND DOCETAXEL WITH OR WITHOUT
TRASTUZUMAB (HERCEPTIN) IN WOMEN WITH METASTATIC BREAST CANCER
Protocol
PROTOCOL
IDS: E-3198
STUDY
CONTACT
Antonio C. Wolff, Chair, Ph: 410-614-4192
Eastern Cooperative Oncology Group
|
PHASE
II STUDY OF HIGH DOSE COMBINATION CHEMOTHERAPY AND AUTOLOGOUS
OR SYNGENEIC PERIPHERAL BLOOD STEM CELL RESCUE FOLLOWED BY IMMUNOTHERAPY
WITH INTERLEUKIN-2 AND SAR-GRAMOSTIM (GM-CSF) IN PATIENTS WITH
INFLAMMATORY STAGE IIIB AND RESPONSIVE METASTATIC STAGE IV BREAST
CANCER Protocol
PROTOCOL
IDS: FHCRC-1229.00; NCI-G98-1399; PSOC-1605
STUDY
CONTACT
Frederick R. Appelbaum, Ph: 206-667-4412
Fred Hutchinson Cancer Research Center
Seattle, Washington
|
| PHASE
II STUDY OF HIGH DOSE TOPOTECAN WITH IFOSFAMIDE AND ETOPOSIDE
FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL RESCUE IN
WOMEN WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: MCC-12220; NCI-G00-1809; MCC-IRB-5699
STUDY
CONTACT
Karen K. Fields, Ph: 813-979-7202
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
|
PHASE
II STUDY OF NEOADJUVANT DOXORUBICIN, CYCLOPHOSPHAMIDE, AND PACLITAXEL
WITH OR WITHOUT TRASTUZUMAB (HERCEPTIN) FOLLOWED BY LOCAL SURGERY
WITH OR WITHOUT ADJUVANT TRASTUZUMAB OR ADJUVANT DOXORUBICIN,
CYCLOPHOSPHAMIDE, PACLITAXEL, AND TRASTUZUMAB IN WOMEN WITH
STAGE IIB, IIIA, IIIB, OR IV BREAST CANCER Protocol
PROTOCOL
IDS: UNC-9818; NCI-G00-1836
STUDY
CONTACT
Mark L. Graham, Ph: 919-859-6631
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
|
| PHASE
II STUDY OF INTERLEUKIN-11 WITH FILGRASTIM (G-CSF) IN THE MOBILIZATION
OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH NON-HODGKIN'S
LYMPHOMA, HODGKIN'S DISEASE, BREAST CANCER, OR OTHER SOLID TUMORS
Protocol
PROTOCOL
IDS: FHCRC-1365.00; NCI-G99-1622
STUDY
CONTACT
Lena Holmberg, Ph: 206-667-6447
Fred Hutchinson Cancer Research Center
Seattle, Washington
|
PHASE
II STUDY OF NEOADJUVANT SEQUENTIAL DOXORUBICIN AND DOCETAXEL
IN WOMEN WITH STAGE III BREAST CANCER Protocol
PROTOCOL
IDS: MCC-11971; NCI-G00-1763; MCC-IRB-5292
STUDY
CONTACT
Susan Minton, Ph: 813-972-4673
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
|
| PHASE
II STUDY OF LY231514 AND GEMCITABINE IN WOMEN WITH METASTATIC
BREAST CANCER Protocol
PROTOCOL
ID: NCCTG-983253
STUDY
CONTACT
Michael J. O'Connell, Chair, Ph: 507-284-2511
North Central Cancer Treatment Group
|
PHASE
II STUDY OF NITROCAMPTOTHECIN IN PATIENTS WITH LOCALLY RECURRENT
OR METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: SUPERGEN-RFS2000-17; IUMC-9906-11
STUDY
CONTACT
Show-Li Sun, Ph: 925-327-0200
SuperGen, Incorporated
San Ramon, California
|
| PHASE
II STUDY OF MITOXANTRONE, LEUCOVORIN CALCIUM, AND FLUOROURACIL
IN ELDERLY WOMEN WITH METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: FRE-GERCOR-SAM-S99-1, EU-20028
STUDY
CONTACTS
E. Carola, Chair
GERCOR
C. Bouleuc, Ph: 01-34-23-23-65
Centre Hospitalier Victor Dupouy
Argenteuil, France
|
PHASE
II STUDY OF NONMYELOBLATIVE ALLOGENEIC PERIPHERAL BLOOD STEM
CELL AND DONOR LYMPHOCYTE INFUSIONS IN PATIENTS WITH REFRACTORY
METASTATIC SOLID TUMORS Protocol
PROTOCOL
ID: NHLBI-99-H-0064
STUDY
CONTACT
Richard W. Childs, Ph: 301-496-5093
National Heart, Lung, and Blood Insitute
Bethesda, Maryland, U.S.A.
|
| PHASE
II STUDY OF ORAL ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH
ADVANCED BREAST CANCER Protocol
PROTOCOL
ID: BRI-BR-14
STUDY
CONTACT
Stanislaw R. Burzynski, Ph: 713-335-5697
Burzynski Research Institute
Houston, Texas
|
PHASE
II STUDY OF T-CELL DEPLETED ALLOGENEIC PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION IN PATIENTS WITH METASTATIC BREAST CANCER
Protocol
PROTOCOL
IDS: NCI-00-C-0119; NCI-1027
STUDY
CONTACT
Michael Bishop, Ph: 301-435-2764
Medicine Branch
Bethesda, Maryland
|
| PHASE
II STUDY OF OXALIPLATIN IN WOMEN WITH ADVANCED OR METASTATIC
BREAST CANCER FOLLOWING FAILURE OF ANTHRACYCLINE/TAXANE BASED
CHEMOTHERAPY Protocol
PROTOCOL
ID: EORTC-16001
STUDY
CONTACT
Pierre Fumoleau, Ph: 33-2-40-67-99-00
CRLCC Nantes - Atlantique
Nantes-Saint Herblain, France
|
PHASE
II STUDY OF THE PREDICTIVE VALUE OF THE EXTREME DRUG RESISTANCE
ASSAY IN PATIENTS RECEIVING PACLITAXEL FOR METASTATIC BREAST
CANCER Protocol
PROTOCOL
IDS: ONCOTECH-OTBR01; NCI-V98-1391;UCIRVINE-97-02
STUDY
CONTACTS
Rita S. Mehta, Chair, Ph: 714-798-5933
Oncotech, Inc.
John Butler, Ph: 714-456-8030
Chao Family Comprehensive Cancer Center
Orange, California
|
| PHASE
II STUDY OF RALOXIFENE AS A CHEMOPREVENTIVE AGENT FOR PREMENOPAUSAL
WOMEN AT HIGH RISK FOR DEVELOPING INVASIVE BREAST CANCER Protocol
PROTOCOL
IDS: NCI-98-C-0123; MB-402
STUDY
CONTACT
JoAnne Zujewski, Ph: 301-402-0985
Medicine Branch
Bethesda, Maryland
|
PHASE
II STUDY OF TOPICAL CERAMIDE CREAM IN WOMEN WITH CUTANEOUS BREAST
CANCER Protocol
PROTOCOL
ID: NCCTG-N0031
STUDY
CONTACT
Michael J. O'Connell, Ph: 507-284-2511
North Central Cancer Treatment Group
|
| PHASE
II STUDY OF REBECCAMYCIN ANALOGUE IN PATIENTS WITH STAGE IIIB
OR IV BREAST CANCER Protocol
PROTOCOL
IDS: DFCI-99283; NCI-197; CWRU-DFCI-1199
STUDY
CONTACT
Harold J. Burstein, Ph: 617-632-3800
Dana-Farber Cancer Insitute
Boston, Massachusetts
|
PHASE
II STUDY OF TRASTUZUMAB (HERCEPTIN) AND PACLITAXEL IN PATIENTS
WITH HER2 OVEREXPRESSING METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: NCI-99-C-0121; NCI-T98-0087
STUDY
CONTACT
Susan Elaine Bates, Ph: 301-402-1357
Medicine Branch
Bethesda, Maryland
|
| PHASE
II STUDY OF TRASTUZUMAB (HERCEPTIN) AND RADIOTHERAPY IN WOMEN
WITH STAGE III OR IV INVASIVE PRIMARY CARCINOMA OF THE BREAST
THAT CONTINUES TO OVEREXPRESS HER2 FOLLOWING NEOADJUVANT CHEMOTHERAPY
Protocol
PROTOCOL
IDS: UNC-9925; NCI-G00-1835
STUDY
CONTACT
Carolyn Sartor, Ph: 919-966-7700
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
|
PHASE
II/III RANDOMIZED STUDY OF FIRST-LINE HORMONAL THERAPY WITH
EXEMESTANE VERSUS TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH LOCALLY
RECURRENT OR METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: EORTC-10951, PHARMACIA-EORTC-10951
STUDY
CONTACT
Robert Paridaens, Chair, Ph: 32-16-346902
EORTC Breast Cancer Group
|
| PHASE
II STUDY OF TRASTUZUMAB (HERCEPTIN) PLUS INTERLEUKIN-2 IN PATIENTS
WITH METASTATIC BREAST CANCER WHO HAVE FAILED PRIOR TRASTUZUMAB
Protocol
PROTOCOL
IDS: OSU-99H0192, NCI-195
STUDY
CONTACT
Charles L. Shapiro, Chair, Ph: 614-293-7530
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio
|
PHASE
III RANDOMIZED COMPARISON OF CYCLOPHOSPHAMIDE/METHOTREXATE/
FLUOROURACIL (CMF) VERSUS SEQUENTIAL EPIRUBICIN FOLLOWED BY
CMF AS ADJUVANT CHEMOTHERAPY FOR WOMEN WITH EARLY STAGE BREAST
CANCER Protocol
PROTOCOL
IDS: SCTN-BR9601; EU-97013
STUDY
CONTACT
Chris Twelves, Chair, Ph: 0141-211-1712
Scottish Cancer Therapy Network
|
| PHASE
II STUDY OF YTTRIUM Y 90 SMT 487 IN PATIENTS WITH REFRACTORY
SMALL CELL LUNG CANCER OR METASTATIC BREAST CANCER EXPRESSING
SOMATOSTATIN RECEPTOR Protocol
PROTOCOL
IDS: MCC-12338; NCI-G00-1858; MCC-IRB-5803; NOVARTIS-CSMT-487A0103
STUDY
CONTACT
Larry K. Kvols, Chair Ph: 813-972-8400, ext. 8286
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
|
PHASE
III RANDOMIZED COMPARISON OF HIGH DOSE CHEMOTHERAPY PLUS FILGRASTIM
TO FILGRASTIM FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS
FOR AUTOLOGOUS TRANSPLANTATION FOR PATIENTS WITH RESPONSIVE
METASTATIC BREAST CANCER OR HIGH RISK STAGE II AND III PATIENTS
Protocol
PROTOCOL
IDS: MDA-DM-95047; NCI-G96-1014
STUDY
CONTACT
James Gajewski, Ph: 713-745-1644
University of Texas - MD Anderson Cancer Center
Houston, Texas
|
| PHASE
II/III RANDOMIZED STUDY OF MONOCLONAL ANTIBODY ABX-CBL VERSUS
ANTI-THYMOCYTE GLOBULIN IN PATIENTS WITH STEROID RESISTANT ACUTE
GRAFT-VERSUS-HOST DISEASE Protocol
PROTOCOL
IDS: UCLA-9911052, NCI-G01-1916, ABX-CB-9906
STUDY
CONTACT
Mary Carol Territo, Chair Ph: 310-825-7768
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
|
PHASE
III RANDOMIZED STUDY OF ADJUVANT CYCLOPHOS-PHAMIDE, METHOTREXATE,
AND FLUOROURACIL WITH OR WITHOUT EPIRUBICIN IN WOMEN WITH EARLY
STAGE BREAST CANCER Protocol
PROTOCOL
IDS: CRC-TU-NEAT; EU-98041
STUDY
CONTACT
Helena Earl, Ph: 01223-274312
Addenbrooke's NHS Trust
Cambridge, England, United Kingdom
|
| PHASE
III RANDOMIZED STUDY OF ADJUVANT DOCETAXEL AND DOXORUBICIN VERSUS
DOXORUBICIN WITH OR WITHOUT CYCLOPHOSPHAMIDE, FOLLOWED BY COMBINATION
CHEMOTHERAPY IN WOMEN WITH NODE POSITIVE BREAST CANCER Protocol
PROTOCOL
IDS: BIG-2-98; EU-20002; RP-56976-V-315
STUDY
CONTACT
Martine J. Piccart-Gebhart, Ph: 32-2-5413206
Institut Jules Bordet
Brussels (Bruxelles), Belgium
|
PHASE
III RANDOMIZED STUDY OF ADJUVANT TAMOXIFEN WITH OR WITHOUT CYCLOPHOSPHAMIDE,
METHOTREXATE, AND FLUOROURACIL (CMF) IN POSTMENOPAUSAL WOMEN
WITH STAGE I-IIIA, UNILATERAL, INVASIVE BREAST CANCER Protocol
PROTOCOL
IDS: SCTN-BR9402; EU-94003; UKCCCR-ABC/BR9402
STUDY
CONTACT
W.D. George, Chair Ph: 0141-211-2166
Scottish Cancer Therapy Network
Glasgow, Scotland, United Kingdom
|
| PHASE
III RANDOMIZED STUDY OF ADJUVANT LETROZOLE VERSUS TAMOXIFEN
IN POSTMENOPAUSAL WOMEN WITH OPERABLE, HORMONE RECEPTOR POSITIVE
BREAST CANCER Protocol
PROTOCOL
IDS: IBCSG-1-98; EU-99022; IBCSG-18-98; NOVARTIS-2026703019
STUDY
CONTACT
Henning T. Mouridsen, Ph: 35454776
Rigshopitalet
Copenhagen, Denmark
|
PHASE
III RANDOMIZED STUDY OF ADJUVANT TAMOXIFEN, OVARIAN SUPPRESSION,
AND/OR CHEMOTHERAPY IN WOMEN WITH STAGE I, II, AND IIIA BREAST
CANCER Protocol
PROTOCOL
IDS: UKCCCR-ABC; EU-94029
STUDY
CONTACT
John Robert Yarnold, Ph: 020-8661-3891
Royal Marsden Hospital
Sutton, England, United Kingdom
|
| PHASE
III RANDOMIZED STUDY OF ADJUVANT TAMOXIFEN WITH OR WITHOUT OVARIAN
SUPPRESSION AND/OR CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL
(CMF) IN PREMENOPAUSAL WOMEN WITH STAGE I-IIIA, UNILATERAL,
INVASIVE BREAST CANCER Protocol
PROTOCOL
IDS: SCTN-BR9401; EU-94002; UKCCCR-ABC/BR9401
STUDY
CONTACT
W.D. George, Chair, Ph: 0141-211-2166
University of Glasgow
Scottish Cancer Therapy Network
Glasgow, Scotland, United Kingdom
|
PHASE
III RANDOMIZED STUDY OF AEROSOLIZED RIBAVIRIN VERSUS STANDARD
SUPPORTIVE THERAPY IN PATIENTS WITH RESPIRATORY SYNCYTIAL VIRUS
FOLLOWING STEM CELL TRANSPLANTATION Protocol
PROTOCOL
IDS: FHCRC-1290.00, NCI-G01-1939
STUDY
CONTACT
Michael Boeckh, Chair Ph: 206-667-4898
Fred Hutchinson Cancer Research Center
Seattle, Washington
|
| PHASE
III RANDOMIZED STUDY OF AEROSOLIZED RIBAVIRIN WITH OR WITHOUT
PALIVIZUMAB IN PATIENTS WITH RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA
FOLLOWING STEM CELL TRANSPLANTATION Protocol
PROTOCOL
IDS: FHCRC-1379.00, NCI-G01-1929
STUDY
CONTACT
Michael Boeckh, Chair Ph: 206-667-4898
Fred Hutchinson Cancer Research Center
Seattle, Washignton
|
PHASE
III RANDOMIZED STUDY OF AMPHOTERICIN B-LIPOSOMAL FORMULATION
INITIATED 72-84 HOURS VS 144-156 HOURS AFTER ONSET OF A FEBRILE
EPISODE IN CANCER PATIENTS WITH GRANULOCYTOPENIA AND PERSISTENT
UNEXPLAINED FEVER REFRACTORY TO ANTIBACTERIALS Protocol
PROTOCOL
IDS: EORTC-19951
STUDY
CONTACT
Claudio Viscoli, Chair Ph: 39-10-5600848/6
EORTC Invasive Fungal Infections Group
|
| PHASE
III RANDOMIZED STUDY OF DOCETAXEL IN PATIENTS WITH METASTATIC
BREAST CANCER Protocol
PROTOCOL
IDS: MDA-ID-99242; NCI-1691; AVENTIS-MDA-ID-99242
STUDY
CONTACT
Edgardo Rivera, Chair, Ph: 713-792-2817
University of Texas - MD Anderson Cancer Center
Houston, Texas
|
PHASE
III RANDOMIZED STUDY OF CASPOFUNGIN ACETATE VERSUS AMPHOTERICIN
B LIPOSOMAL IN PATIENTS WITH PERSISTENT FEVER AND NEUTROPENIA
FOLLOWING TREATMENT FOR CANCER Protocol
PROTOCOL
IDS: MSKCC-00085; NCI-G00-1898; MERCK-026-01
STUDY
CONTACT
Kent Sepkowitz, Ph: 212-639-2375
Memorial Sloan-Kettering Cancer Center
New York, New York
|
| PHASE
III RANDOMIZED STUDY OF DOCETAXEL VERSUS PACLITAXEL IN WOMEN
WITH METASTATIC OR LOCALLYADVANCED, INOPERABLE ADENOCARCINOMA
OF THE BREAST Protocol
PROTOCOL
IDS: AVENTIS-56976-TAX-311; NCI-V95-0680; RP-56976-TAX-311
STUDY
CONTACT
Peter Marcus Ravdin, Chair Ph: 210-567-4777
Aventis Pharmaceuticals, Inc.
|
PHASE
III RANDOMIZED STUDY OF CHEMOTHERAPY AND SURGERY COMPARING ADJUVANT
DOXORUBICIN FOLLOWED BY CMF (CYCLOPHOSPHAMIDE, METHOTREXATE,
AND FLUOROURACIL) VERSUS ADJUVANT DOXORUBICIN AND PACLITAXEL
FOLLOWED BY CMF VERSUS PRIMARY DOXORUBICIN AND PACLITAXEL FOLLOWED
BY CMF IN WOMEN WITH OPERABLE BREAST CANCER AND TUMOR GREATER
THAN 2 CENTIMETERS Protocol
PROTOCOL
IDS: INT-23/96; EU-97001
STUDY
CONTACT
Gianni Bonadonna, Ph: 2-2390352
Instituto Nazionale per lo Studio e la Cura dei Tumori
Milano (Milan), Italy
|
| PHASE
III RANDOMIZED STUDY OF DOXORUBICIN IN COMBINATION WITH EITHER
DOCETAXEL OR CYCLOPHOSPHAMIDE IN WOMEN WITH POTENTIALLY OPERABLE,
LOCALLY ADVANCED OR INFLAMMATORY BREAST CANCER Protocol
PROTOCOL
IDS: SCTN-BR9809; EU-98053
STUDY
CONTACT
T.R.J. Evans, Ph: 0141-330-4171
C.R.C. Beatson Laboratories
Glasgow, Scotland, United Kingdom
|
PHASE
III RANDOMIZED STUDY OF EPOETIN ALFA IN ANEMIC PATIENTS WITH
ADVANCED CANCER UNDERGOING CHEMOTHERAPY Protocol
PROTOCOL
IDS: NCCTG-979253; NCI-P98-0133
STUDY
CONTACT
Thomas E. Witzig, Chair Ph: 507-284-2176
North Central Cancer Treatment Group
|
| PHASE
III RANDOMIZED STUDY OF HIGH-DOSE CYCLOPHOS-PHAMIDE, THIOTEPA,
AND CARBOPLATIN AND AUTOLOGOUS BONE MARROW OR PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION IN CONJUNCTION WITH CYCLOSPORINE AND
INTERFERON GAMMA VERSUS INTERLEUKIN-2 AS IMMUNOMODULATION IN
WOMEN WITH HIGH-RISK STAGE II OR III BREAST CANCER Protocol
PROTOCOL
IDS: CPMC-IRB-7608; NCI-G00-1890; CPMC-CAMP-014
STUDY
CONTACT
Charles S. Hesdorffer, Ph: 212-305-4907
Herbert Irving Comprehensive Cancer Center
New York, New York, U.S.A.
|
PHASE
III RANDOMIZED STUDY OF PACLITAXEL WITH OR WITHOUT GEMCITABINE
IN WOMEN WITH UNRESECTABLE, LOCALLY RECURRENT, OR METASTATIC
BREAST CANCER Protocol
PROTOCOL
ID: LILLY-B9E-MC-JHQG
STUDY
CONTACTS
Furhan Yunus, Chair, Ph: 901-725-1785
Eli Lilly and Company
John M. Waples, Ph: 256-551-6546
Comprehensive Cancer Institute of Huntsville
Huntsville, Alabama
|
| PHASE
III RANDOMIZED STUDY OF ITRACONAZOLE VERSUS FLUCONAZOLE TO PREVENT
ASGERGILLUS INFECTIONS IN PATIENTS UNDERGOING PERIPHERAL BLOOD
STEM CELL OR BONE MARROW TRANSPLANTATION Protocol
PROTOCOL
IDS: FHCRC-1322.00, NCI-H99-0030
STUDY
CONTACT
Kieren A. Marr, Chair Ph: 206-667-2995
Fred Hutchinson Cancer Research Center
Seattle, Washington
|
PHASE
III RANDOMIZED STUDY OF VALGANCICLOVIR TO PREVENT LATE CYTOMEGALOVIRUS
INFECTION IN PATIENTS WHO HAVE UNDERGONE ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION Protocol
PROTOCOL
IDS: FHCRC-1577.00, NCI-H01-0072
STUDY
CONTACT
Michael Boeckh, Chair Ph: 206-667-4898
Fred Hutchinson Cancer Research Center
Seattle, Washington
|
| PHASE
III RANDOMIZED STUDY OF MITOXANTRONE WITH OR WITHOUT DOCETAXEL
AS FIRST-LINE CHEMOTHERAPY FOR WOMEN WITH POOR RISK METASTATIC
BREAST CANCER Protocol
PROTOCOL
IDS: GER-AIO-01/92; EU-93011
STUDY
CONTACT
Else G. Heidemann, Chair Ph: 0711-991-3501
Arbeitsgemeinschaft fur Internistische Onkologie
Diakonissen Hospital
Stuttgart, Germany
|
PHASE
III STUDY OF MAINTENANCE IMMUNOTHERAPY WITH CORYNEBACTERIUM
GRANULOSUM P40 IN PATIENTS WITH COLON CANCER, BREAST CANCER,
OR MELANOMA WITH MINIMAL RESIDUAL DISEASE AFTER SURGICAL RESECTION
Protocol
PROTOCOL
IDS: ARG-CO/BR-1
STUDY
CONTACT
Hugo Omar De Carli, Chair Ph: 021-84-3119
Centro Oncologico de Excelencia
Gonnet, Buenos Aires, Argentina
|
| PHASE
IV STUDY OF LETROZOLE AS FIRST-LINE THERAPY IN POSTMENOPAUSAL
WOMEN WITH METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH
TAMOXIFEN Protocol
PROTOCOL
IDS: NOVARTIS-CFEM345A-US10
STUDY
CONTACT
Mildred Ortu Kowalski, Chair Ph: 973-781-5943
Novartis Pharmaceuticals Corporation
|
GENETIC
MAPPING OF INTERACTIVE SUSCEPTIBILITY LOCI IN PATIENTS AND SIBLINGS
WITH BREAST, COLON, LUNG, OR PROSTATE CANCER Protocol
PROTOCOL
IDS: E-1Y97
STUDY
CONTACT
Theodore G. Krontiris, Ph: 626-359-8111
Beckman Research Institute, City of Hope
Los Angeles, California
|
| RANDOMIZED
STUDY OF CONVENTIONAL CARE WITH OR WITHOUT CANCER CARE INTERVENTION
IN PATIENTS WITH BREAST, OVARIAN, PANCREATIC, ENDOMETRIAL, COLON,
OR LUNG CANCER OR NON-HODGKIN'S LYMPHOMA WHO ARE RECEIVING CHEMOTHERAPY
AS PRIMARY TREATMENT Protocol
PROTOCOL
IDS: NCI-P00-0166; MSU-1386005984A1; MSU-9906; MSU-IRB-96479
STUDY
CONTACT
Barbara A. Given, Ph: 517-353-4920
Michigan State University
East Lansing, Michigan
|
GENETIC,
CLINICAL, AND EPIDEMIOLOGICAL STUDY OF INDIVIDUALS AND FAMILIES
AT HIGH RISK OF CANCER Protocol
PROTOCOL
IDS: NCI-78-C-0039
STUDY
CONTACT
Margaret A. Tucker, Ph: 301-496-4375
Genetic Epidemiology Branch
Bethesda, Maryland
|
|
RANDOMIZED
STUDY OF VINORELBINE COMBINED WITH CHRONOMODULATED FLUOROURACIL
IN PREVIOUSLY TREATED WOMEN WITH METASTATIC BREAST CANCER
Protocol
PROTOCOL
IDS: EORTC-05971
STUDY
CONTACT
Bruno Coudert, Ph: 03-80-73-75-28
Centre de Lute Contre le Cancer, Georges-Francois Leclerc
Dijon, France
|
RANDOMIZED
PILOT STUDY TO EVALUATE EDUCATIONAL INTERVENTION AND BEHAVIORAL
SKILLS TRAINING FOR PAIN CONTROL IN PATIENTS WITH RECURRENT
OR METASTATIC BREAST OR PROSTATE CANCER Protocol
PROTOCOL
IDS: E-3Z93; NCI-P95-0068
STUDY
CONTACT
Charles Cleeland, Chair, Ph: 713-745-3470
Eastern Cooperative Oncology Group
|
|
RANDOMIZED
STUDY OF BRIEF PHYSICIAN-INITIATED SMOKING CESSATION STRATEGIES
VERSUS USUAL CARE IN PATIENTS WITH EARLY STAGE CANCER WHO
ARE UNDERGOING TREATMENT IN CLINICAL ONCOLOGY SETTINGS Protocol
PROTOCOL
IDS: NCI-P93-0042; E-1Y92
STUDY
CONTACT
Neal Richard Boyd, Jr., Chair, Ph: 215-728-6900
Eastern Cooperative Oncology Group
|
SCREENING
AND DIAGNOSTIC STUDY OF DIGITAL MAMMOGRAPHY VERSUS SCREEN-FILM
MAMMOGRAPHY IN THE DETECTION OF BREAST CANCER IN WOMEN Protocol
PROTOCOL
IDS: ACRIN-6652
STUDY
CONTACT
Etta Pisano, Chair, Ph: 919-966-6957
Hancock Memorial Hospital
|
|
SCREENING
STUDY FOLLOWING LOCAL EXCISION IN SELECTED PATIENTS WITH DUCTAL
CARCINOMA IN SITU (DCIS) OF THE BREAST Protocol
PROTOCOL
ID: E-5194
STUDY
CONTACT
Lorie L. Hughes, Chair, Ph: 404-233-4960
Eastern Cooperative Oncology Group
|
SCREENING
AND DIAGNOSTIC STUDY OF MAGNETIC RESONANCE IMAGING IN WOMEN
WITH SUSPECTED BREAST CANCER Protocol
PROTOCOL
IDS: UPCC-ACR-6884
STUDY
CONTACT
Mitchell Schnall, Ph: 215-662-7238
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
|
|
SCREENING
STUDY OF BREAST IMAGING OUTCOME MEASURES AND PHASE OF MENSTRUAL
CYCLE IN WOMEN AT HIGH GENETIC RISK OF BREAST CANCER Protocol
PROTOCOL
ID: NCI-01-C-0008
STUDY
CONTACT
Ruthann M. Giusti, Chair Ph: 301-496-1611
Division of Cancer Epidemiology and Genetics
|
PHASE
I STUDY OF SU006668 IN PATIENTS WITH ADVANCED SOLID TUMORS Protocol
PROTOCOL
IDS: UCLA-0004061; NCI-GO1-2010; SUGEN-SU6668.004
STUDY
CONTACT
Lee S. Rosen, Chair Ph: 310-206-3170
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
|
|
STUDY
OF STEM CELL AUGMENTED, ELUTRIATED GRAFTS FOR PREVENTION OF
GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC
BONE MARROW TRANSPLANTATION Protocol
PROTOCOL
IDS: JHOC-97021903; NCI-V98-1460; JHOC-J9711
STUDY
CONTACT
Paul V. O'Donnell, Ph: 410-614-0205
Johns Hopkins Oncology Center
Baltimore, Maryland
|
PHASE
I STUDY OF VINORELBINE AND TRANSTUZUMAB (HERCEPTIN) IN PATIENTS
WITH HER-2/NEU OVEREXPRESSINIG REFRACTORY LOCALLY ADVANCED OR
METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: DMS-9904; NCI-G01-1932
STUDY
CONTACT
Peter A. Kaufman, Chair Ph: 603-650-6700
Norris Cotton Cancer Center
Lebanon, New Hampshire, U.S.A.
|
|
PHASE
I STUDY OF PHOTODYNAMIC THERAPY WITH SILICON POTHALOCYANINE
4 IN PATIENTS WITH CUTANEOUS MALIGNANCIES Protocol
PROTOCOL
IDS: CWRU-1Y97; NCI-T99-0007
STUDY
CONTACT
Scot C. Remick, Chair Ph: 216-844-1196
Ireland Cancer Center
Cleveland, Ohio
|
PHASE
I/II STUDY OF INTRAHEPATIC DOXORUBICIN ADSORBED TO MAGNETIC
TARGETED CARRIERS IN PATIENTS WITH METASTATIC CANCER TO THE
LIVER OR ADVANCED HEPATOCELLULAR CARCINOMA Protocol
PROTOCOL
IDS: FERX-MTC-DOX-003; UCSF-00454; UCSF-H5535-17999-01D
STUDY
CONTACT
Joy Koda, Chair Ph: 858-677-7788
FeRx Incorporated
|
|
PHASE
II STUDY OF CP-358,774 IN WOMEN WITH PROGRESSIVE OR RECURRENT,
LOCALLY ADVANCED OR METASTATIC BREAST CANCER Protocol
PROTOCOL
IDS: MSKCC-01068; NCI-G01-2012; GENEN-TECH- OSI2288g
STUDY
CONTACT
Maura Dickler, Chair Ph: 212-639-5456
Memorial Sloan-Kettering Cancer Center
New York, New York
|
PHASE
I/II STUDY OF TRASTUZUMAB (HERCEPTIN) AND IRESSA IN PATIENTS
WITH METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2-NEU Protocol
PROTOCOL
IDS: E-1100
STUDY
CONTACT
Robert L. Comis, Chair Ph: 215-789-3645
Eastern Cooperative Oncology Group
|
|
COMPARATIVE
GENETIC STUDY OF SUSCEPTIBILITY GENOTYPES AND PROTEIN EXPRESSION
IN HEALTHY WOMEN, WOMEN AT HIGH RISK FOR BREAST CANCER, AND
WOMEN WITH BREAST CANCER Protocol
PROTOCOL
IDS: NCI-00-C-0079
STUDY
CONTACT
Pamela Klein, Chair Ph: 301-295-3899
Center for Cancer Research
Bethesda, Maryland
|
|
